menu
    • menu
    [{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Taro Pharmaceuticals"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Juyou Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Juyou Biotechnology"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Croma-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Croma Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Croma Pharma"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ STADA"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Egis Pharmaceuticals PLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Crescita Therapeutics \/ Egis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Egis Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Tetracaine

    Menu

    Tetracaine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Egis Pharmaceuticals PLC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

                            Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : $0.7 million

                            December 13, 2021

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Egis Pharmaceuticals PLC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : STADA Arzneimittel

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®

                            Details : Under the terms of the Agreement, STADA will be responsible for commercializing Pliaglis in the Territories utilizing its experienced sales force.

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 18, 2021

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : STADA Arzneimittel

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Croma-Pharma

                            Deal Size : $1.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®

                            Details : Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other mi...

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 28, 2021

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Croma-Pharma

                            Deal Size : $1.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Juyou Biotechnology

                            Deal Size : $2.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Announces Licensing Agreement for Pliaglis® in China

                            Details : Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : $0.1 million

                            November 05, 2020

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Juyou Biotechnology

                            Deal Size : $2.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Crescita Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Taro Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement

                            Details : The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : $3.9 million

                            July 28, 2020

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Taro Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth